Orkambi Approved in Europe for Younger CF Patients with F508del Mutations
cystic fibrosis, News
The European Commission has approved the label extension of Orkambi (lumacaftor/ivacaftor) for the treatment of children ages 2-5 with cystic fibrosis (CF) due to F508del mutations, Vertex Pharmaceuticals, the ... Read more